Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definition
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Atrial fibrillation drugs industry 3600 synopsis, 2014 - 2025 (USD Million)
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Atrial fibrillation type trends
2.1.4. Application trends
2.1.5. Route of Administration trends
2.1.6. End-use trends
2.1.7. Regional trends
Chapter 3. Atrial Fibrillation Drugs Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2014 - 2025 (USD Million)
3.3. Industry impact factors
3.3.1. Growth drivers
3.3.1.1. Increase in prevalence of cardiovascular diseases in developed regions of North America and Europe
3.3.1.2. Rise in demand and need for unmet atrial fibrillation drug therapy
3.3.1.3. Growing geriatric population in Asia Pacific and Latin America
3.3.1.4. Launch of Direct Oral Anticoagulants (DOACs)
3.3.2. Industry pitfalls & challenges
3.3.2.1. High cost of the anticoagulant drugs
3.3.2.2. Adverse drug side effects
3.3.2.3. Lack of awareness regarding medical therapy in underdeveloped and developing regions
3.4. Growth potential analysis
3.4.1. By product
3.4.2. By atrial fibrillation type
3.4.3. By application
3.4.4. By route of administration
3.4.5. By end-use
3.5. Global atrial fibrillation prevalence, 2017
3.6. Drug approval scenario
3.6.1. U.S. FDA (U.S. Food and Drug Administration)
3.6.2. Europe EMA (European Medicines Agency)
3.6.3. China CFDA (China Drug Administration)
3.6.4. Australia TGA (Australian Therapeutic Goods Administration)
3.7. Proportion of atrial fibrillation patients on atrial fibrillation drug therapy, 2018
3.7.1. North America
3.7.2. Europe
3.7.3. Asia Pacific
3.7.4. Latin America
3.7.5. Middle East and Africa
3.8. Proportion of atrial fibrillation patients on direct oral anticoagulants (DOACs) drug therapy
3.8.1. North America
3.8.2. Europe
3.8.3. Asia Pacific
3.8.4. Latin America
3.8.5. Middle East and Africa
3.9. Atrial fibrillation drugs pricing analysis
3.9.1. Antiarrhythmic drugs
3.9.2. Anticoagulant drugs
3.10. Major atrial fibrillation anticoagulant drugs market share analysis, 2017
3.11. Global atrial fibrillation drugs prescription pattern, 2014 – 2025
3.11.1. Antiarrhythmic drugs
3.11.2. Anticoagulant drugs
3.11.2.1. Vitamin K antagonists (Warfarin)
3.11.2.2. Novel oral anticoagulants (NOACs)
3.11.2.2.1. Direct thrombin inhibitors (Dabigatran - Pradaxa)
3.11.2.2.2. Direct factor Xa inhibitors
3.11.2.2.2.1. Apixaban (Eliquis)
3.11.2.2.2.2. Betrixaban (Bevyxxa)
3.11.2.2.2.3. Edoxaban (Savaysa/Lixiana)
3.11.2.2.2.4. Rivaroxaban (Xarelto)
3.12. Technology landscape
3.12.1. New atrial fibrillation drugs
3.12.1.1. Antiarrhythmic drugs
3.12.1.2. Anticoagulant drugs
3.12.2. Future of drug therapy in atrial fibrillation
3.12.2.1. Antiarrhythmic drugs
3.12.2.2. Anticoagulant drugs
3.13. Porter’s analysis
3.14. Competitive landscape, 2017
3.14.1. Strategy dashboard
3.15. PESTEL analysis
Chapter 4. Atrial Fibrillation Drugs Market, By Product
4.1. Global atrial fibrillation drugs market share, by product, 2018 & 2025
4.2. Antiarrhythmic Drugs
4.2.1. Market size, by region, 2014 – 2025 (USD Million)
4.3. Anticoagulant Drugs
4.3.1. Market size, by region, 2014 – 2025 (USD Million)
4.3.2. Vitamin K antagonists (VKA)
4.3.2.1. Market size, by region, 2014 – 2025 (USD Million)
4.3.3. Novel oral anticoagulants (NOACs)
4.3.3.1. Market size, by region, 2014 – 2025 (USD Million)
4.3.3.2. Direct thrombin inhibitors
4.3.3.2.1. Market size, by region, 2014 – 2025 (USD Million)
4.3.3.3. Direct factor Xa inhibitors
4.3.3.3.1. Market size, by region, 2014 – 2025 (USD Million)
Chapter 5. Atrial Fibrillation Drugs Market, By Atrial Fibrillation Type
5.1. Global atrial fibrillation drugs market share, by atrial fibrillation type, 2018 & 2025
5.2. Paroxysmal
5.2.1. Market size, by region, 2014 – 2025 (USD Million)
5.3. Persistent
5.3.1. Market size, by region, 2014 – 2025 (USD Million)
5.4. Permanent
5.4.1. Market size, by region, 2014 – 2025 (USD Million)
Chapter 6. Atrial Fibrillation Drugs Market, By Application
6.1. Global atrial fibrillation drugs market share, by application, 2018 & 2025
6.2. Heart Rhythm Control
6.2.1. Market size, by region, 2014 – 2025 (USD Million)
6.3. Heart Rate Control
6.3.1. Market size, by region, 2014 – 2025 (USD Million)
Chapter 7. Atrial Fibrillation Drugs Market, By Route of Administration
7.1. Global atrial fibrillation drugs market share, by route of administration, 2018 & 2025
7.2. Oral
7.2.1. Market size, by region, 2014 – 2025 (USD Million)
7.3. Injectable
7.3.1. Market size, by region, 2014 – 2025 (USD Million)
Chapter 8. Atrial fibrillation Drugs Market, By End-use
8.1. Global atrial fibrillation drugs market share by end-use, 2018 & 2025
8.2. Hospitals
8.2.1. Market size, by region, 2014 – 2025 (USD Million)
8.3. Cardiac Centers
8.3.1. Market size, by region, 2014 – 2025 (USD Million)
8.4. Ambulatory Surgical Centers
8.4.1. Market size, by region, 2014 – 2025 (USD Million)
8.5. Others
8.5.1. Market size, by region, 2014 – 2025 (USD Million)
Chapter 9. Atrial Fibrillation Drugs Market, By Region
9.1. Global atrial fibrillation drugs market share by region, 2018 & 2025
9.2. North America
9.2.1. Market size, by country, 2014 – 2025 (USD Million)
9.2.2. Market size, by product, 2014 – 2025 (USD Million)
9.2.2.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.2.2.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.2.3. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.2.4. Market size, by application, 2014 – 2025 (USD Million)
9.2.5. Market size, by route of administration, 2014 – 2025 (USD Million)
9.2.6. Market size, by end-use, 2014 – 2025 (USD Million)
9.2.7. U.S.
9.2.7.1. Market size, by product, 2014 – 2025 (USD Million)
9.2.7.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.2.7.1.1.1. Market size, by Novel oral anticoagulants, 2014 – 2025 (USD Million)
9.2.7.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.2.7.3. Market size, by application, 2014 – 2025 (USD Million)
9.2.7.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.2.7.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.2.8. Canada
9.2.8.1. Market size, by product, 2014 – 2025 (USD Million)
9.2.8.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.2.8.1.1.1. Market size, by Novel oral anticoagulants, 2014 – 2025 (USD Million)
9.2.8.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.2.8.3. Market size, by application, 2014 – 2025 (USD Million)
9.2.8.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.2.8.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3. Europe
9.3.1. Market size, by country, 2014 – 2025 (USD Million)
9.3.2. Market size, by product, 2014 – 2025 (USD Million)
9.3.2.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.2.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.3. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.4. Market size, by application, 2014 – 2025 (USD Million)
9.3.5. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.6. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.7. Germany
9.3.7.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.7.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.7.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.7.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.7.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.7.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.7.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.8. UK
9.3.8.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.8.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.8.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.8.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.8.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.8.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.8.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.9. France
9.3.9.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.9.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.9.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.9.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.9.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.9.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.9.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.10. Spain
9.3.10.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.10.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.10.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.10.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.10.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.10.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.10.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.11. Italy
9.3.11.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.11.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.11.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.11.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.11.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.11.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.11.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.12. Russia
9.3.12.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.12.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.12.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.12.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.12.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.12.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.12.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.13. Poland
9.3.13.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.13.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.13.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.13.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.13.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.13.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.13.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.14. Switzerland
9.3.14.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.14.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.14.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.14.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.14.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.14.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.14.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.15. Belgium
9.3.15.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.15.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.15.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.15.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.15.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.15.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.15.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.16. Czech Republic
9.3.16.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.16.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.16.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.16.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.16.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.16.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.16.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.17. Netherlands
9.3.17.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.17.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.17.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.17.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.17.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.17.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.17.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.18. Sweden
9.3.18.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.18.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.18.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.18.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.18.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.18.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.18.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.19. Hungary
9.3.19.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.19.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.19.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.19.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.19.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.19.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.19.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.20. Austria
9.3.20.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.20.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.20.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.20.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.20.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.20.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.20.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.21. Portugal
9.3.21.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.21.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.21.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.21.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.21.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.21.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.21.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.22. Denmark
9.3.22.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.22.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.22.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.22.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.22.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.22.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.22.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.23. Norway
9.3.23.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.23.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.23.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.23.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.23.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.23.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.23.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.24. Finland
9.3.24.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.24.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.24.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.24.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.24.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.24.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.24.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.25. Ireland
9.3.25.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.25.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.25.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.25.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.25.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.25.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.25.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.26. Turkey
9.3.26.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.26.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.26.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.26.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.26.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.26.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.26.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.3.27. Greece
9.3.27.1. Market size, by product, 2014 – 2025 (USD Million)
9.3.27.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.3.27.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.3.27.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.3.27.3. Market size, by application, 2014 – 2025 (USD Million)
9.3.27.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.3.27.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.4. Asia Pacific
9.4.1. Market size, by country, 2014 – 2025 (USD Million)
9.4.2. Market size, by product, 2014 – 2025 (USD Million)
9.4.2.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.4.2.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.4.3. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.4.4. Market size, by application, 2014 – 2025 (USD Million)
9.4.5. Market size, by route of administration, 2014 – 2025 (USD Million)
9.4.6. Market size, by end-use, 2014 – 2025 (USD Million)
9.4.7. China
9.4.7.1. Market size, by product, 2014 – 2025 (USD Million)
9.4.7.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.4.7.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.4.7.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.4.7.3. Market size, by application, 2014 – 2025 (USD Million)
9.4.7.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.4.7.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.4.8. Japan
9.4.8.1. Market size, by product, 2014 – 2025 (USD Million)
9.4.8.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.4.8.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.4.8.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.4.8.3. Market size, by application, 2014 – 2025 (USD Million)
9.4.8.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.4.8.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.4.9. India
9.4.9.1. Market size, by product, 2014 – 2025 (USD Million)
9.4.9.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.4.9.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.4.9.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.4.9.3. Market size, by application, 2014 – 2025 (USD Million)
9.4.9.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.4.9.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.4.10. Australia
9.4.10.1. Market size, by product, 2014 – 2025 (USD Million)
9.4.10.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.4.10.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.4.10.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.4.10.3. Market size, by application, 2014 – 2025 (USD Million)
9.4.10.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.4.10.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.4.11. South Korea
9.4.11.1. Market size, by product, 2014 – 2025 (USD Million)
9.4.11.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.4.11.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.4.11.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.4.11.3. Market size, by application, 2014 – 2025 (USD Million)
9.4.11.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.4.11.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.4.12. Taiwan
9.4.12.1. Market size, by product, 2014 – 2025 (USD Million)
9.4.12.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.4.12.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.4.12.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.4.12.3. Market size, by application, 2014 – 2025 (USD Million)
9.4.12.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.4.12.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.4.13. New Zealand
9.4.13.1. Market size, by product, 2014 – 2025 (USD Million)
9.4.13.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.4.13.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.4.13.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.4.13.3. Market size, by application, 2014 – 2025 (USD Million)
9.4.13.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.4.13.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.4.14. Singapore
9.4.14.1. Market size, by product, 2014 – 2025 (USD Million)
9.4.14.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.4.14.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.4.14.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.4.14.3. Market size, by application, 2014 – 2025 (USD Million)
9.4.14.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.4.14.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.5. Latin America
9.5.1. Market size, by country, 2014 – 2025 (USD Million)
9.5.2. Market size, by product, 2014 – 2025 (USD Million)
9.5.2.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.5.2.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.5.3. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.5.4. Market size, by application, 2014 – 2025 (USD Million)
9.5.5. Market size, by route of administration, 2014 – 2025 (USD Million)
9.5.6. Market size, by end-use, 2014 – 2025 (USD Million)
9.5.7. Brazil
9.5.7.1. Market size, by product, 2014 – 2025 (USD Million)
9.5.7.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.5.7.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.5.7.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.5.7.3. Market size, by application, 2014 – 2025 (USD Million)
9.5.7.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.5.7.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.5.8. Argentina
9.5.8.1. Market size, by product, 2014 – 2025 (USD Million)
9.5.8.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.5.8.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.5.8.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.5.8.3. Market size, by application, 2014 – 2025 (USD Million)
9.5.8.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.5.8.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.5.9. Venezuela
9.5.9.1. Market size, by product, 2014 – 2025 (USD Million)
9.5.9.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.5.9.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.5.9.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.5.9.3. Market size, by application, 2014 – 2025 (USD Million)
9.5.9.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.5.9.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.5.10. Columbia
9.5.10.1. Market size, by product, 2014 – 2025 (USD Million)
9.5.10.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.5.10.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.5.10.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.5.10.3. Market size, by application, 2014 – 2025 (USD Million)
9.5.10.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.5.10.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.5.11. Mexico
9.5.11.1. Market size, by product, 2014 – 2025 (USD Million)
9.5.11.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.5.11.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.5.11.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.5.11.3. Market size, by application, 2014 – 2025 (USD Million)
9.5.11.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.5.11.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.6. Middle East & Africa
9.6.1. Market size, by country, 2014 – 2025 (USD Million)
9.6.2. Market size, by product, 2014 – 2025 (USD Million)
9.6.2.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.6.2.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.6.3. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.6.4. Market size, by application, 2014 – 2025 (USD Million)
9.6.5. Market size, by route of administration, 2014 – 2025 (USD Million)
9.6.6. Market size, by end-use, 2014 – 2025 (USD Million)
9.6.7. South Africa
9.6.7.1. Market size, by product, 2014 – 2025 (USD Million)
9.6.7.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.6.7.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.6.7.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.6.7.3. Market size, by application, 2014 – 2025 (USD Million)
9.6.7.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.6.7.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.6.8. Saudi Arabia
9.6.8.1. Market size, by product, 2014 – 2025 (USD Million)
9.6.8.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.6.8.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.6.8.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.6.8.3. Market size, by application, 2014 – 2025 (USD Million)
9.6.8.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.6.8.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.6.9. UAE
9.6.9.1. Market size, by product, 2014 – 2025 (USD Million)
9.6.9.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.6.9.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.6.9.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.6.9.3. Market size, by application, 2014 – 2025 (USD Million)
9.6.9.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.6.9.5. Market size, by end-use, 2014 – 2025 (USD Million)
9.6.10. Egypt
9.6.10.1. Market size, by product, 2014 – 2025 (USD Million)
9.6.10.1.1. Market size, by anticoagulant drugs, 2014 – 2025 (USD Million)
9.6.10.1.1.1. Market size, by novel oral anticoagulants, 2014 – 2025 (USD Million)
9.6.10.2. Market size, by atrial fibrillation type, 2014 – 2025 (USD Million)
9.6.10.3. Market size, by application, 2014 – 2025 (USD Million)
9.6.10.4. Market size, by route of administration, 2014 – 2025 (USD Million)
9.6.10.5. Market size, by end-use, 2014 – 2025 (USD Million)
Chapter 10. Company Profiles
10.1. AstraZeneca
10.1.1. Business overview
10.1.2. Financial data
10.1.3. Product landscape
10.1.4. Strategic outlook
10.1.5. SWOT analysis
10.2. Boehringer Ingelheim
10.2.1. Business overview
10.2.2. Financial data
10.2.3. Product landscape
10.2.4. Strategic outlook
10.2.5. SWOT analysis
10.3. Bristol-Myers Squibb
10.3.1. Business overview
10.3.2. Financial data
10.3.3. Product landscape
10.3.4. Strategic outlook
10.3.5. SWOT analysis
10.4. Daiichi Sankyo
10.4.1. Business overview
10.4.2. Financial data
10.4.3. Product landscape
10.4.4. Strategic outlook
10.4.5. SWOT analysis
10.5. GlaxoSmithKline
10.5.1. Business overview
10.5.2. Financial data
10.5.3. Product landscape
10.5.4. Strategic outlook
10.5.5. SWOT analysis
10.6. Johnson and Johnson (JanssenOrtho)
10.6.1. Business overview
10.6.2. Financial data
10.6.3. Product landscape
10.6.4. Strategic outlook
10.6.5. SWOT analysis
10.7. Mitsubishi Tanabe Pharma
10.7.1. Business overview
10.7.2. Financial data
10.7.3. Product landscape
10.7.4. Strategic outlook
10.7.5. SWOT analysis
10.8. Pfizer
10.8.1. Business overview
10.8.2. Financial data
10.8.3. Product landscape
10.8.4. Strategic outlook
10.8.5. SWOT analysis
10.9. Portola Pharmaceuticals
10.9.1. Business overview
10.9.2. Financial data
10.9.3. Product landscape
10.9.4. Strategic outlook
10.9.5. SWOT analysis
10.10. Sanofi
10.10.1. Business overview
10.10.2. Financial data
10.10.3. Product landscape
10.10.4. Strategic outlook
10.10.5. SWOT analysis
